A review of hematopoietic cell transplantation in China: data and trends during 2008-2016. (Q36354948)

13 August 2017

title

A review of hematopoietic cell transplantation in China: data and trends during 2008-2016. (English)

1 reference

13 August 2017

L-P Xu

1

1 reference

13 August 2017

D-P Wu

2

1 reference

13 August 2017

M-Z Han

3

1 reference

13 August 2017

H Huang

4

1 reference

13 August 2017

Q-F Liu

5

1 reference

13 August 2017

D-H Liu

6

1 reference

13 August 2017

Z-M Sun

7

1 reference

13 August 2017

L-H Xia

8

1 reference

13 August 2017

J Chen

9

1 reference

13 August 2017

H-X Wang

10

1 reference

13 August 2017

C Wang

11

1 reference

13 August 2017

C-F Li

12

1 reference

13 August 2017

Y-R Lai

13

1 reference

13 August 2017

J-M Wang

14

1 reference

13 August 2017

D-B Zhou

15

1 reference

13 August 2017

H Chen

16

1 reference

13 August 2017

Y-P Song

17

1 reference

13 August 2017

T Liu

18

1 reference

13 August 2017

K-Y Liu

19

1 reference

13 August 2017

X-J Huang

20

1 reference

13 August 2017

language of work or name

English

0 references

publication date

24 April 2017

1 reference

Bone Marrow Transplantation

13 August 2017

published in

1 reference

Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Who is the best donor for a related HLA haplotype-mismatched transplant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

7 January 2021

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

7 January 2021

Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

7 January 2021

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

7 January 2021

Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

7 January 2021

Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.59

7 January 2021

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Tra

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28436973

12 December 2020

inferred from PubMed ID database lookup

[Haploidentical transplantation for the treatment of intermediate- or high- risk acute myeloid leukemia in first complete remission: guideline and practice]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28436973

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/BMT.2017.59

1 reference

13 August 2017

1 reference